ClinicalTrials.gg
RecruitingNCT07148193PROSa+Updated Dec 8, 2025

Quality of Life and Medical Care of Long-term Sarcoma Survivors in Germany (PROSa+)

An observational study in Sarcoma, Survivorship and Quality of Life (QOL), sponsored by Technische Universität Dresden. Recruiting at 5 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-08.

Sponsored by Technische Universität Dresden · Observational

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Cross-sectional
Enrollment
1,600
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 103 studies in Sarcoma with a site in Germany — 21 open to participants now, 30 under way, 3 of them phase 3. Sarcoma · Germany.

Planned enrollment
4th of 19
1,600 · median 130
Started
2025
with 5 others
Observational
19 of 103
7 open now
Primary completion
2027-09
later than 15 of 29 live
Registered
100th of 103
by date

Among the 103 studies in Sarcoma with a site in Germany, this one is the 4th largest by planned enrollment of the 19 observational ones that give a count, is one of 6 that started in 2025, is one of 19 observational ones, reaches primary completion later than 15 of the 29 other live ones, and was the 100th registered.

Sarcoma

1,610 studies on the registry are indexed under Sarcoma; 367 are open to participants now.

Browse Sarcoma studies →

Open to participants now

21 of the 103 studies in Sarcoma with a site in Germany are open now. Recruiting first, the newest first:

15 more — sign in →

All 21 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 302 Sarcoma studies recruiting now, 192 (64%) set no upper age limit and 83 (27%) stop at 75 or younger; 94 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 103 studies in Sarcoma with a site in Germany, or all of them as a file.
02

Study summary

The study PROSa+ aims to assess patient-reported outcomes (PROs), patient-reported experiences (PREs), and the socioeconomic situation of long-term sarcoma survivors (≥ 5 years post-diagnosis, with or without active disease) in Germany. The mixed-methods research design includes a multicenter observational study with a cross-sectional questionnaire survey involving 1,600 participants (paper, online), qualitative interviews with up to 60 participants, and longitudinal analyses combining data from existing sarcoma registries and the previous PROSa study conducted between 2017 and 2020.

Read the detailed description

Sarcomas are rare cancers that can arise almost anywhere in the body and account for only about one percent of all cancer diagnoses. Both the disease and its treatments often result in late effects, yet knowledge about these long-term consequences remains limited. The study PROSa+ aims to assess patient-reported outcomes (PROs), patient-reported experiences (PREs), and the socioeconomic situation of long-term sarcoma survivors (≥ 5 years post-diagnosis, with or without active disease) in Germany. Particular focus is placed on subgroups with potential long-term risks, including survivors of bone sarcomas, extremity or trunk sarcomas after multimodal treatment, retroperitoneal sarcomas, gastrointestinal stromal tumors (GIST) with or without long-term TKI therapy, and young adult survivors.

The mixed-methods research design includes a multicenter observational study with a one-time questionnaire survey involving 1,600 participants (paper, online), qualitative interviews with up to 60 participants, and longitudinal analyses combining data from existing sarcoma registries and the previous PROSa study conducted between 2017 and 2020.

Recruitment is built on draws on existing network structures, including the PROSa cohort, the National Center for Tumor Diseases (NCT/UCC) Dresden, the SarcBOP registry at the National Center for Tumor Diseases (NCT) Heidelberg, West German Cancer Center Essen (WTZ), University Hospital Mannheim (UMM), the German Sarcoma Foundation, and cooperating sarcoma centers. Medical data are extracted from patient records.

Statistical analyses will include descriptive statistics and regression models to identify impaired quality of life domains and associated factors.

03

Conditions studied

  • Sarcoma
  • Survivorship
  • Quality of Life (QOL)
  • Medical Care

Keywords

  • Sarcoma
  • Neoplasms
  • Patient-Reported Outcomes
  • Patient-Reported Experiences
  • Medical Care
  • Quality of Life
  • Unmet Health Needs
  • Oncology
  • Psycho-Oncology
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults (≥18 years) diagnosed with a sarcoma at least five years prior to study participation, regardless of current disease status, who are treated or receive follow-up care in Germany.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of sarcoma according to the International Classification of Diseases for Oncology (ICD-O) and World Health Organization (WHO) classification, including soft tissue sarcoma, bone sarcoma, and GIST
  • At least 5 years since initial sarcoma diagnosis
  • With or without active disease
  • Age ≥18 years at the time of study participation

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of Desmoid tumors
  • Inability to complete a structured questionnaire (e.g., due to insufficient German language skills, cognitive impairment, dementia)
05

Study design

Observational model
Case-only
Time perspective
Cross-sectional
Enrollment
1,600 participants (estimated)
Patient registry
No

Groups and cohorts

  • Sarcoma survivors

    Adults (≥18 years) diagnosed with a sarcoma at least five years prior to study participation, regardless of current disease status, who are treated or receive follow-up care in Germany.

    Other: No intervention (observational study)

Interventions

  • OtherNo intervention (observational study)

    No intervention (observational study)

06

What researchers measure

Primary outcomes

  1. Quality of Life (EORTC QLQ-SURV100)

    The EORTC QLQ-SURV100 is a 100-item questionnaire assessing general quality of life among cancer survivors. It includes multiple functional scales covering physical, role, emotional, cognitive, and social functioning, as well as symptom scales (fatigue, pain) and several single-item measures. Most items are rated on a 1-4 scale, while two global items on overall quality of life and general health are rated on a 1-7 scale. Higher scores on the functional and global health status scales indicate better quality of life, whereas higher scores on symptom scales reflect worse quality of life. With the exception of five acute symptoms, the SURV100 includes all items from the EORTC QLQ-C30. To enable comparative analyses, the investigators supplemented the SURV100 with these five missing items: appetite loss, nausea, vomiting, constipation, and diarrhea.

    Time frame: single-time point (enrollment)

  2. Satisfaction with Medical Care (adapted from EORTC OUT-PATSAT7 & self-developed items)

    Satisfaction with medical care and communication will be assessed using three items adapted from the EORTC OUT-PATSAT7 and three self-developed items, all rated on a 1-5 scale. Higher scores indicate greater satisfaction with the medical care received.

    Time frame: single time point (enrollment)

  3. Use of Care Offers (self-developed, adapted from CaSUN)

    Service utilization will be assessed with self-developed items based on the Cancer Survivors' Unmet Needs measure (CaSUN). Participants indicate their use of 24 different non-rehabilitation care services and 11 rehabilitation care services. Response options include two types of "No" (offer not available or offer available but not used) and, if "Yes," a rating from 1-3 indicating how helpful the offer was, with higher scores reflecting greater helpfulness.

    Time frame: single time point (enrollment)

  4. Unmet Needs (self-developed, adapted from CaSUN)

    Unmet needs will be assessed with self-developed items based on the CaSUN, asking participants about the lack of adequate support or services in 20 areas. Response options include two types of "No" (no need or need has already been met) and, if "Yes," a rating from 1-3 indicating the current intensity of the unmet need, with higher scores reflecting greater unmet need.

    Time frame: single time point (enrollment)

Secondary outcomes

  1. Fatigue (EORTC QLQ-FA12)

    Fatigue will be assessed using the 12-item EORTC QLQ-FA12 scale, which measures physical, emotional, and cognitive aspects of cancer-related fatigue on a 1-4 scale. Higher scores indicate greater fatigue.

    Time frame: single-time point (enrollment)

  2. Psychological Distress (PHQ-4)

    Psychological distress will be measured using the four-item PHQ-4, including the diagnostic core criteria for depression (PHQ-2) and generalized anxiety disorder (GAD-2), ranging from 1-4. Higher scores indicate greater psychological distress.

    Time frame: single-time point (enrollment)

  3. Loneliness (UCLA LS-3)

    Loneliness will be assessed using the three-item UCLA Loneliness Scale, measuring subjective feelings of loneliness and social isolation, ranging from 1-3. Higher scores indicate greater loneliness.

    Time frame: single-time point (enrollment)

  4. Physical Complaints (EORTC WISP)

    Physical complaints will be measured using the EORTC WISP module, allowing participants to report up to three symptoms and rate the degree of burden from 1-4. Higher scores indicate greater impairment due to the respective symptom.

    Time frame: single-time point (enrollment)

  5. Communication with Healthcare Professionals (adapted from EORTC COMU26 & self-developed items)

    Communication experiences will be assessed using nine items adapted from the EORTC COMU26 and nine self-developed items, focusing on perceived quality and clarity of communication with healthcare providers. Rated on a 1-4 scale, higher scores indicate greater satisfaction with communication.

    Time frame: single-time point (enrollment)

  6. Information Sources (self-developed, answer options adapted from CaSUN)

    Information sources will be assessed using nine self-developed items, asking participants where they obtain cancer-related information. Response options include two types of "No" (not known or known but not used) and, if "Yes," a rating from 1-3 indicating how helpful the source was, with higher scores reflecting greater helpfulness.

    Time frame: single-time point (enrollment)

  7. Sociodemographic Items

    Sociodemographic characteristics, including age, sex, and migration background will be collected.

    Time frame: single-time point (enrollment)

  8. Socioeconomic Items

    Socioeconomic status will be assessed through items measuring i.a. education, employment status, and income.

    Time frame: single-time point (enrollment)

  9. Physical Activity (adapted Godin-Shephard Leisure-Time Physical Activity Questionnaire)

    Physical activity will be measured using an adapted version of the Godin-Shephard Leisure-Time Physical Activity Questionnaire. This 4-item questionnaire evaluates the frequency and duration of mild, moderate and vigorous aerobic activities, as well as moderate-to-vigorous strength training, performed during the week. Scores reflect whether participants meet exercise guidelines: * Aerobic guidelines: ≥75 min of vigorous or ≥150 min moderate activity (meeting guidelines) vs. 0-149 minutes of moderatre and vigorous activity per week (not meeting guidelines) * Resistance guidelines: ≥2 resistance sessions/week (meeting guidelines) vs. \<2 sessions (not meeting guidelines) Higher scores indicate better adherence to physical activity recommendations.

    Time frame: single-time point (enrollment)

  10. Comorbidities

    Information on comorbid conditions (e.g., cardiovascular disease, diabetes, depression) will be collected, capturing co-existing health conditions. The total number of comorbidities will be summed and used as a control variable in the analyses.

    Time frame: single-time point (enrollment)

07

Study locations

4 of 5 sites recruiting
  • Technical University Dresden
    Dresden, Saxony, Germany
    Recruiting
  • University Hospital Essen
    Essen, Germany
    Not yet recruiting
    • Uta Dirksen, Prof. Dr. · Contact
  • NCT Heidelberg
    Heidelberg, Germany
    Recruiting
    • Richard F. Schlenk, Prof. Dr. · Contact
  • Sarcoma Center Mannheim
    Mannheim, Germany
    Recruiting
    • Jens Jakob, Prof. Dr. · Contact
  • Deutsche Sarkom-Stiftung
    Wölfersheim, Germany
    Recruiting
    • Markus Wartenberg · Contact
08

References and documents

Related links

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2025 (actual). Primary completion is estimated for Sep 2027, 22 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2025
First posted
Aug 29, 2025
StartActual
Nov 28, 2025
Primary completionEst.
Sep 2027
CompletionEst.
Sep 2027
Last update
Dec 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07148193
Collaborators
German Sarcoma Foundation (DSS), German Cancer Research Center, Universitätsmedizin Mannheim, University Hospital, Essen, National Centre for Tumor Diseases Heidelberg
Responsible party
Martin Eichler (Head of the Core Unit Patient-Reported Outcomes at NCT/UCC Dresden, Technische Universität Dresden) — Principal investigator
First posted
Aug 29, 2025
Start date
Nov 28, 2025
Primary completion
Sep 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Dec 8, 2025

Study contacts

Tanja Strukelj, M. A.
Contact
tanja.strukelj@ukdd.de,
+493514587056
Patricia Blickle, M. Sc.
Contact
patricia.blickle@dkfz-heidelberg.de
+49221423506
Martin Eichler, Dr.
principal investigator · TU Dresden & NCT/ UCC Dresden
Karen Steindorf, Prof. Dr.
principal investigator · DKFZ Heidelberg
Richard F. Schlenk, Prof. Dr.
principal investigator · University Hospital Heidelberg
Jens Jakob, Prof. Dr.
principal investigator · Sarcoma Center Mannheim
Uta Dirksen, Prof. Dr.
principal investigator · University Hospital, Essen
Markus Wartenberg
principal investigator · Deutsche Sarkom-Stiftung

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion